Note: The comments under each article title are the opinion of our president, Al Musella, DPM, and do not reflect official policy of the Musella Foundation!
06/02/18 Returning to work after multimodal treatment in glioblastoma patients.
Returning to work after multimodal treatment in glioblastoma patients. This is one of the most important outcome of brain tumor treatments. It should be considered an important primary endpoint for clinical trials: what % of patients are able to work full time at the level of their previous job at 1,2,3 year point? What % of patients can work at least part time at any job at 1,2,3 years. This is important because for the first time, we are seeing long term survivors of GBMs who can actually work full time at high level jobs, many years down the line. Even if a treatment only improves median survival by a small amount, but allows those who do survive to engage in meaningful work - that is a breakthrough. For example, many years ago there were reports of a high % of long term survivors with intense radiation. However, it caused so much damage that most survivors were bedridden for the rest of their lives. More recently, with DC-Vax, ICT-107, Toca 511 / Toca FC, and others, we see some long term survivors who are functioning at the highest level - executive jobs, having families, driving and enjoying life. That is what we strive for. So it should be a formal endpoint!